[an error occurred while processing this directive]
Skip to Main Content

Latest News

Advertise Here
July 5, 2010
Volume 88, Number 27
p. 8

Targeting Disease

Drug Discovery: Natural products may not be the best place to look for small molecules to treat human ailments

Celia Arnaud

  • Print this article
  • Email the editor

Latest News

October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

Small-molecule natural products target essential proteins rather than those involved in disease, according to a new study (J. Am. Chem. Soc., DOI: 10.1021/ja102798t). Stuart L. Schreiber of the Broad Institute of Harvard and MIT says his team’s findings suggest that drug designers hoping to hit disease proteins will have to look beyond nature for inspiration.

Using network analysis, Schreiber, Paul A. Clemons, and coworkers show that natural products bind to proteins that interact with many other proteins, a hallmark of gene products encoded by essential genes. In contrast, proteins encoded by disease genes tend to have fewer interactions. In addition, the researchers find, approved synthetic drugs tend to strike proteins with network connectivity that more closely resembles that of disease proteins than that of natural-product targets.

“Clearly, natural products can become drugs because many of them are drugs,” Schreiber says. But his team set out to determine whether natural products are optimal compounds for targeting disease proteins. “Our data suggest they are not,” he says. “This is a great challenge for synthetic organic chemistry: How do we turn our attention to new classes of compounds that target disease gene products?”

The fact that natural products aim at proteins encoded by essential genes is not surprising, Schreiber says. Many of them evolved as weapons in microbial warfare, he explains, and “they will target the most essential genes possible.”

“The idea that natural products might be less suited as drugs for human diseases due to evolutionary direction toward highly connected and essential biological processes is significant,” says John A. Porco Jr. of Boston University. “Such fundamental observations are an excellent step toward understanding how we should consider development of new drugs for human disease.”

“Alas, as would have been expected from professor Schreiber and from the Broad Institute, the paper makes a strong case for the idea that the diversity required for pharma-level success is not likely to be provided by strictly small-molecule natural products,” says Samuel J. Danishefsky of Columbia University. But the “paper admirably serves to refocus reader interest on small-molecule natural products as well as synthesis. That’s all to the good.”

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!